Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer

This study evaluated the use of pendant-based wearables for monitoring digital biomarkers of frailty in predicting chemotherapy resilience among 27 veteran cancer patients (average age: 64.6 ± 13.4 years), undergoing bi-weekly chemotherapy. Immediately following their first day of chemotherapy cycle...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-01, Vol.14 (1), p.2612-11, Article 2612
Main Authors: Cay, Gozde, Sada, Yvonne H., Dehghan Rouzi, Mohammad, Uddin Atique, Md Moin, Rodriguez, Naima, Azarian, Mehrnaz, Finco, M. G., Yellapragada, Sarvari, Najafi, Bijan
Format: Article
Language:English
Subjects:
631/67
639/166/985
692/53/2423
Aged
Biomarkers
Chemotherapy
Energy expenditure
Exercise
Frailty
Frailty - diagnosis
Humanities and Social Sciences
Humans
Middle Aged
multidisciplinary
Neoplasms - drug therapy
Physical activity
Regression analysis
Resilience, Psychological
Science
Science (multidisciplinary)
Veterans
Wearable Electronic Devices
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study evaluated the use of pendant-based wearables for monitoring digital biomarkers of frailty in predicting chemotherapy resilience among 27 veteran cancer patients (average age: 64.6 ± 13.4 years), undergoing bi-weekly chemotherapy. Immediately following their first day of chemotherapy cycle, participants wore a water-resistant pendant sensor for 14 days. This device tracked frailty markers like cadence (slowness), daily steps (inactivity), postural transitions (weakness), and metrics such as longest walk duration and energy expenditure (exhaustion). Participants were divided into resilient and non-resilient groups based on adverse events within 6 months post-chemotherapy, including dose reduction, treatment discontinuation, unplanned hospitalization, or death. A Chemotherapy-Resilience-Index (CRI) ranging from 0 to 1, where higher values indicate poorer resilience, was developed using regression analysis. It combined physical activity data with baseline Eastern Cooperative Oncology Group (ECOG) assessments. The protocol showed a 97% feasibility rate, with sensor metrics effectively differentiating between groups as early as day 6 post-therapy. The CRI, calculated using data up to day 6 and baseline ECOG, significantly distinguished resilient (CRI = 0.2 ± 0.27) from non-resilient (CRI = 0.7 ± 0.26) groups (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-53025-z